Accumulation of genomic aberrations during clinical progression of medulloblastoma

Acta Neuropathologica

Volumn 116, Issue 4, 2008, Pages 383-390

  Korshunov, Andrey ^a,b   Benner, Axel ^a   Remke, Marc ^a   Lichter, Peter ^a   Deimling, Andreas ^a,b   Pfister, Stefan ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anaplasia; Chromosome17q; Genomic aberration; Medulloblastoma; Metastasis; Progression

Indexed keywords

CISPLATIN; LOMUSTINE; MYC PROTEIN; ONCOPROTEIN; PROTEIN MYCN; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER GROWTH; CHILD; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 6Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERPHASE; MALE; MEDULLOBLASTOMA; MENINGEAL METASTASIS; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; TUMOR BIOPSY;

ADOLESCENT; ADULT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 6; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MEDULLOBLASTOMA; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR MARKERS, BIOLOGICAL;

EID: 51849085106     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-008-0422-y     Document Type: Article

References (27)

1. Albright A, Wisoff J, Zeltzer P, Boyett J, Rorke L, Stanley P (1996) Effects of medulloblastoma resections on outcome in children: A report from the Children's Cancer Group. Neurosurgery 38(2):265-271. doi: 10.1097/00006123-199602000-00007
2. Clifford S, Lusher M, Lindsey J et al (2006) Wnt/wingless pathway activation and chromosome 6 loss characterise a distinct molecular sub-group of medulloblastomas associated with a favourable prognosis. Cell Cycle 5(22):2666-2670
3. Eberhart C, Burger P (2003) Anaplasia and grading in medulloblastomas. Brain Pathol 13(3):376-385
4. Eberhart C, Cohen K, Tihan T, Goldthwaite P, Burger P (2003) Medulloblastomas with systemic metastases: Evaluation of tumor histopathology and clinical behavior in 23 patients. J Pediatr Hematol Oncol 25(3):198-203. doi: 10.1097/00043426-200303000-00004
5. Eberhart C, Kepner J, Goldthwaite P et al (2002) Histopathologic grading of medulloblastomas: A Pediatric Oncology Group study. Cancer 94(2):552-560. doi: 10.1002/cncr.10189
6. Eberhart C, Kratz J, Schuster A et al (2002) Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 12(1):36-44
7. Eberhart C, Kratz J, Wang Y et al (2004) Histopathological and molecular prognostic markers in medulloblastoma: C-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63(5):441-449
8. Ellison DW, Onilude OE, Lindsey JC et al (2005) β-Catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23(31):7951-7957. doi: 10.1200/JCO.2005.01.5479
9. Gajjar A, Hernan R, Kocak M et al (2004) Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22(6):984-993. doi: 10.1200/ JCO.2004.06.032
10. Giangaspero F, Wellek S, Masuoka J, Gessi M, Kleihues P, Ohgaki H (2006) Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol 112(1):5-12. doi: 10.1007/s00401-006-0064-x
11. Gilbertson R, Wickramasinghe C, Hernan R et al (2001) Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85(5):705-712. doi: 10.1054/bjoc.2001.1987
12. Giordana M, D'Agostino C, Pollo B et al (2005) Anaplasia is rare and does not influence prognosis in adult medulloblastoma. J Neuropathol Exp Neurol 64(10):869-874
13. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW (2004) Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10(16):5482-5493. doi: 10.1158/ 1078-0432.CCR-03-0721
14. McManamy C, Lamont J, Taylor R et al (2003) Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 62(6):627-632
15. Mendrzyk F, Radlwimmer B, Joos S et al (2005) Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 23(34):8853-8862. doi: 10.1200/ JCO.2005.02.8589
16. Min H, Lee Y, Park K, Cho B, Park S (2006) Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior. Acta Neuropathol 112(1):13-20. doi: 10.1007/s00401-006-0073-9
17. Neben K, Korshunov A, Benner A et al (2004) Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64(9):3103-3111. doi: 10.1158/ 0008-5472.CAN-03-3968
18. Pan E, Pellarin M, Holmes E et al (2005) Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 11(13):4733-4740. doi: 10.1158/1078-0432.CCR-04-0465
19. Pfister S, Remke M, Benner A, et al (2008) Molecular risk stratification of pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q, 17q, and the MYC/MYCN loci. J Clin Oncol (in revision)
20. Pfister S, Remke M, Toedt G et al (2007) Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. Genes Chromosomes Cancer 46(9):839-851. doi: 10.1002/gcc.20471
21. Polkinghorn W, Tarbell N (2007) Medulloblastoma: Tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4(5):295-304. doi: 10.1038/ncponc0794
22. Ray A, Ho M, Ma J et al (2004) A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 10(22):7613-7620. doi: 10.1158/1078-0432.CCR-04-0499
23. Rutkowski S, von Bueren A, von Hoff K et al (2007) Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 13(9):2651-2657. doi: 10.1158/ 1078-0432.CCR-06-1779
24. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sorensen N, Kuhl J (1998) Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 16(7):2478-2485
25. Thompson MC, Fuller C, Hogg TL et al (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24(12):1924-1931. doi: 10.1200/JCO.2005.04.4974
26. Zeltzer PM, Boyett JM, Finlay JL et al (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17(3):832-845
27. Zerbini C, Gelber R, Weinberg D et al (1993) Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol 11(4):616-622